Workshop addresses oncology dose optimization across full span of development

BY CHELSEY MCINTYRE, PHARMD, KARI OAKES

In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities. On the first day, discussants looked at how to tackle first-in human trials, weighed the importance of the maximum tolerated dose, and looked at the evolving concept of the clinical utility index.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap